Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061205 | 0.83 | RAB9A (0.40) | ALDH1A1HTTLMNAKDM4ERAB9A | |
| SCHEMBL5373022 | 0.83 | ADH1B (0.42) | LMNAMAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL6376648 | 0.77 | CHRNB2 (0.51) | CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL7063618 | 0.77 | HDAC3 (0.35) | CYP1A2MAPTTP53CYP3A4RAB9A | |
| SCHEMBL7061210 | 0.74 | SMN1; SMN2 (0.42) | ALDH1A1CHRM2KDM4EKMT2AMEN1 | |
| SCHEMBL7110560 | 0.71 | LMNA (0.35) | ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL7665647 | 0.71 | CYP1A2 (0.62) | CYP1A2CYP2D6ALDH1A1NPSR1HTT | |
| SCHEMBL7059655 | 0.69 | TSHR (0.41) | ALDH1A1HTTLMNAMAPTPOLB | |
| SCHEMBL5767277 | 0.69 | ESR1 (0.41) | — | |
| SCHEMBL13154263 | 0.69 | CYP1A2 (0.59) | CYP1A2CYP2D6ALDH1A1NPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1248621-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001047523-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | OPRK1, OPRD1, ACHE | CYP1A2 678/4885CYP2D6 337/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.